Posters

Visual improvement in adult amblyopic eyes with high myopia or astigmatism after phakic anterior chamber intraocular lens implantation

Poster Details

First Author: P.Rodrigues PORTUGAL

Co Author(s):                        

Abstract Details

Purpose:

To report 16 cases of visual improvement after phakic anterior chamber intraocular lens (IOL) implantation, in adult eyes with high myopia, or high astigmatism, or both, and anisometropic amblyopia

Setting:

Department of Ophthalmology, Hospital Pedro Hispano, Unidade Local de Sa�Ã�ºde de Matosinhos, Porto, Portugal

Methods:

Retrospective study, with revision of all consecutive medical records of sixteen eyes of sixteen patients (14 women and 2 man, mean age 32,56 years), presenting high myopia or high astigmatism, or a combination of both, and some degree of anisometropic amblyopia, with long standing documentation, that were submitted to implantation of anterior chamber phakic IOL (3 Artisan and 13 Artiflex, Ophtec, 10 of them toric), by the same Surgeon (PR), between December 2012 and June 2016, and followed for at least 6 months after surgery.

Results:

There was a statistically significant improvement in uncorrected (UCVA) and best-corrected (BCVA) visual acuity versus preoperative values, with a mean improvement of 3,71 lines in BCVA. 8 eyes reached a final BCVA equal or better than the non-amblyopic eye. The spherical equivalent (SE) was in between half a diopter in 11 eyes and bellow one diopter in all eyes studied. None complication was demonstrated along the follow-up period. Mean endothelial cell loss was 2.12% at the last follow-up visit.

Conclusions:

This study indicates that anterior chamber phakic IOL implantation may be an effective surgical alternative for the correction of high refractive errors in adult eyes with anisometropic amblyopia, leading to a possible improvement of vision in eyes well beyond the age generally considered to be responsive to anti-amblyopic treatment. However, additional cases and longer follow-up periods are needed to confirm these results and to assess possible complications.

Financial Disclosure:

NONE